Ipsen
Works in Cardiovascular · Dermatology · Genetic & rare · GI & liver · Hematology · Immunology · Metabolic & endocrine · Musculoskeletal · Neurology · Oncology · Psychiatry · Renal & urogenital · Respiratory · Women's health
Ipsen is a clinical trial sponsor. It has 34 active clinical trials with 9,292 planned participants, across 14 therapeutic areas. Since 2021 it has completed 78 trials and stopped 20 early.
Trial track record · since 2021
Pipeline · 34 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
6 approved drug applications with a product on the market.
Questions about Ipsen
Ipsen is lead sponsor of 34 active clinical trials on ClinicalTrials.gov, with 9,292 planned participants, in Cardiovascular, Dermatology, Genetic & rare, GI & liver and other areas. Since 2021 it has completed 78 trials and stopped 20 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Ipsen; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-06.
Approve Suite is not affiliated with Ipsen. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.